Impact of New Drugs for Therapeutic Intervention in Alzheimer’s Disease

Olloquequi, Jordi; Ettcheto, Miren; Cano, Amanda; Carrasco, Marina; Espinosa, Triana; Beas‐Zárate, Carlos; Gudiño-Cabrera, Graciela; Ureña‐Guerrero, Mónica E.; Verdaguer, Ester; Folch, Jaume; Auladell, Carme; Camins, Antoni

doi:10.31083/j.fbl2705146

Cited by 13 publications

(12 citation statements)

References 149 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Donanemab, another humanized mAb from Eli Lilly & Co., recognizing Aβ(p3-42) a pyroglutamate form of Aβ that is aggregated in amyloid plaques [ 63 , 64 , 65 ]. This humanized IgG1 antibody is currently being tested on AD patients with prodromal to moderate AD in a phase III clinical trial [ 66 , 67 ].…”

Section: Current Treatment Strategies Targeting Aβmentioning

confidence: 99%

Alzheimer’s Disease: A Brief History of Immunotherapies Targeting Amyloid β

Vogt

Jennings²,

Mohsen

et al. 2023

IJMS

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is the most common form of dementia and may contribute to 60–70% of cases. Worldwide, around 50 million people suffer from dementia and the prediction is that the number will more than triple by 2050, as the population ages. Extracellular protein aggregation and plaque deposition as well as accumulation of intracellular neurofibrillary tangles, all leading to neurodegeneration, are the hallmarks of brains with Alzheimer’s disease. Therapeutic strategies including active and passive immunizations have been widely explored in the last two decades. Several compounds have shown promising results in many AD animal models. To date, only symptomatic treatments are available and because of the alarming epidemiological data, novel therapeutic strategies to prevent, mitigate, or delay the onset of AD are required. In this mini-review, we focus on our understanding of AD pathobiology and discuss current active and passive immunomodulating therapies targeting amyloid-β protein.

show abstract

Section: Current Treatment Strategies Targeting Aβmentioning

confidence: 99%

Alzheimer’s Disease: A Brief History of Immunotherapies Targeting Amyloid β

Vogt

Jennings²,

Mohsen

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Baik and colleagues demonstrated that in an LPS-induced mouse model of cognitive decline, LPS robustly enhances mTOR and HIF1α transcription [ 144 ]. Activated mammalian targets of rapamycin complex 1 (mTORC1) strongly hamper autophagy through phosphorylation of p70S6K [ 145 ].…”

Section: Microglia Impairment Heralds Brain Connectivity Dysfunctionmentioning

confidence: 99%

Microglia dynamics in aging-related neurobehavioral and neuroinflammatory diseases

Javanmehr

Saleki

Alijanizadeh

et al. 2022

J Neuroinflammation

View full text Add to dashboard Cite

Microglia represent the first line of immune feedback in the brain. Beyond immune surveillance, they are essential for maintaining brain homeostasis. Recent research has revealed the microglial cells' spatiotemporal heterogeneity based on their local and time-based functions in brain trauma or disease when homeostasis is disrupted. Distinct "microglial signatures" have been recorded in physiological states and brain injuries, with discrete or sometimes overlapping pro- and anti-inflammatory functions. Microglia are involved in the neurological repair processes, such as neurovascular unit restoration and synaptic plasticity, and manage the extent of the damage due to their phenotype switching. The versatility of cellular phenotypes beyond the classical M1/M2 classification, as well as the double-edge actions of microglia in neurodegeneration, indicate the need for further exploration of microglial cell dynamics and their contribution to neurodegenerative processes. This review discusses the homeostatic functions of different microglial subsets focusing on neuropathological conditions. Also, we address the feasibility of targeting microglia as a therapeutic strategy in neurodegenerative diseases.

show abstract

“…For a long time, the FDA has approved only four drugs for the treatment of AD. These medications consist of three cholinesterase inhibitors (donepezil, galantamine, and rivastigmine) and an N-methyl-D-aspartate receptor antagonist (memantine) [32]. In recent years, Chinese-approved sodium oligomannate and FDA-approved adacunumab were used to slow the progression of AD [32].…”

Section: Introductionmentioning

confidence: 99%

American Ginseng for the Treatment of Alzheimer’s Disease: A Review

et al. 2023

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a prevalent degenerative condition that is increasingly affecting populations globally. American ginseng (AG) has anti-AD bioactivity, and ginsenosides, as the main active components of AG, have shown strong anti-AD effects in both in vitro and in vivo studies. It has been reported that ginsenosides can inhibit amyloid β-protein (Aβ) production and deposition, tau phosphorylation, apoptosis and cytotoxicity, as well as possess anti-oxidant and anti-inflammatory properties, thus suppressing the progression of AD. In this review, we aim to provide a comprehensive overview of the pathogenesis of AD, the potential anti-AD effects of ginsenosides found in AG, and the underlying molecular mechanisms associated with these effects. Additionally, we will discuss the potential use of AG in the treatment of AD, and how ginsenosides in AG may exert more potent anti-AD effects in vivo may be a direction for further research.

show abstract

Impact of New Drugs for Therapeutic Intervention in Alzheimer’s Disease

Cited by 13 publications

References 149 publications

Alzheimer’s Disease: A Brief History of Immunotherapies Targeting Amyloid β

Alzheimer’s Disease: A Brief History of Immunotherapies Targeting Amyloid β

Microglia dynamics in aging-related neurobehavioral and neuroinflammatory diseases

American Ginseng for the Treatment of Alzheimer’s Disease: A Review

Contact Info

Product

Resources

About